Mayo Clinic model predicts therapy benefits for gastric cancer patients

The use of genomic sequencing to predict the likelihood that gastric cancer patients will  benefit from chemotherapy or from immunotherapy has been validated by findings in a study published Feb. 9 in Nature Communications.